Evidence for prevention of renal dysfunction associated with primary myelofibrosis by cytoreductive therapy.
Fukuda Y, Araki M, Yamamoto K, Morishita S, Inano T, Misawa K, Ochiai T, Edahiro Y, Imai M, Yasuda H, Gotoh A, Ohsaka A, Komatsu N.
Fukuda Y, et al. Among authors: gotoh a.
Haematologica. 2019 Nov;104(11):e506-e509. doi: 10.3324/haematol.2018.208876. Epub 2019 Apr 4.
Haematologica. 2019.
PMID: 30948490
Free PMC article.
No abstract available.